Skip to main content
Clinical Trials/NL-OMON48661
NL-OMON48661RecruitingNot Applicable

Potassium supplementation in patients with chronic kidney disease and healthy subjects: effects on potassium and sodium balance - Acute K+ balance

Inwendige geneeskunde/Nefrologie0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Adult patients (>= 18 years) with CKD 3b or 4 (45 - 15 ml/min/1.73 m2).
  • Hypertension (defined as office blood pressure > 140/90 mmHg and using single
  • RAAS inhibitor treatment)., Healthy subjects:
  • Healthy adults (>= 18 years), as determined by a responsible and experienced
  • physician, based on a medical evaluation including medical history, physical
  • examination (PE) and laboratory tests carried out in the screening visit (V0).
  • Using no medication (excluding contraceptives).

Exclusion Criteria

  • Hyperkalemia (serum potassium > 5.5 mmol/l).
  • Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor
  • blockers, potassium-sparing diuretics, or oral potassium binders.
  • Patients with previous history of ventricular cardiac arrhythmia.
  • Patients with diabetes mellitus.
  • Patients with a life expectancy < 6 months.
  • Expected initiation of renal replacement therapy < 6 months.
  • Incapacitated subjects.
  • Women who are pregnant, breastfeeding or consider pregnancy in the coming 6
  • months., Healthy subjects:
  • Hyperkalemia (serum potassium > 5.5 mmol/l).
  • Women who are pregnant, breastfeeding or consider pregnancy in the coming 6
  • An office blood pressure >= 140/90 mmHg.
  • A body mass index >= 30 kg/m2.
  • A major illness in the past 3 months or any significant chronic medical
  • illness that the investigator would deem unfavourable for enrolment, including
  • diabetes mellitus.
  • A history of any type of malignancy within the past 5 years with the
  • exception of successfully treated basal cell carcinoma of the skin.
  • A history of any renal disease.
  • A history of any blood clotting disorders.
  • A history of any auto-immune disease.
  • A history of cardiovascular disease (in the past 6 months) defined as
  • documented coronary artery disease including myocardial infarction (MI),
  • (un-)stable angina pectoris or acute coronary syndrome (ACS), percutaneous
  • transluminal coronary angioplasty (PTCA), coronary artery bypass grafting
  • (CABG), cerebrovascular disease, including ischaemic and haemorrhagic stroke or
  • a subarachnoid bleeding (SAB), or peripheral artery disease, including aortic
  • aneurysmata (AA).
  • A history of ventricular cardiac arrhythmia.
  • Any significant sign or symptom of hypotension.

Investigators

Sponsor
Inwendige geneeskunde/Nefrologie

Similar Trials

Potassium supplementation in patients with... | Clinical Trial